نتایج جستجو برای: chronic myeloid leukemia stem cells

تعداد نتایج: 2040664  

Journal: :Current Hematologic Malignancy Reports 2012

2007
Hui-Chi Hsu

Chronic myeloproliferative disorders (MPDs), first proposed by Dameshek in 1951, are clonal hematopoietic stem cell disorders characterized by proliferation of 1 or more myeloid cell lineages in the bone marrow and increased numbers of mature and immature cells in peripheral blood.1 According to the World Health Organization classification, MPDs include polycythemia vera (PV), essential thrombo...

Journal: :international journal of hematology-oncology and stem cell research 0
ardeshir ghavamzadeh hematology-oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, iran kamran alimoghaddam hematology-oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, iran seyyedasadollah mousavi hematology-oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, iran babak bahar hematology-oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, iran masoud iravani hematology-oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, iran amir hamdi hematology-oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, iran

post-remission treatment in patients with acute myeloid leukemia is still controversial. one potent choice for patients with no donor available is autologous stem cell transplantation. the median follow-up period was 18 months and the median age was 26 years old. in the review of 116 recently diagnosed aml patients (except aml- m3) who underwent autologous stem cell transplantation, 72.4% of pa...

Journal: :Blood 2003
Claudia S Huettner Steffen Koschmieder Hiromi Iwasaki Junko Iwasaki-Arai Hanna S Radomska Koichi Akashi Daniel G Tenen

The BCR/ABL fusion protein is found in more than 90% of patients with chronic myeloid leukemia (CML) as well as in a subset of patients with acute B-cell leukemia. We have previously described a transgenic model for an inducible and reversible acute B-cell leukemia caused by p210 BCR/ABL. Here, we describe a new model of an inducible BCR/ABL disease by directing the expression of the oncogene t...

Journal: :Vojnosanitetski Pregled 2022

Introduction. Extramedullary sites of leukemic proliferation, harboring an adverse outcome, are rare and usually found in the blastic phase chronic myeloid leukemia. We report a case newly diagnosed patient with leukemia phase, infiltration right ovary on disease presentation. Case report. The presented abdominal pain, leukocytosis, anemia. A peripheral blood smear indicated leukemia, cytoreduc...

Journal: :The Journal of clinical investigation 2005
Björn de Rijke Agnes van Horssen-Zoetbrood Jeffrey M Beekman Britt Otterud Frans Maas Rob Woestenenk Michel Kester Mark Leppert Anton V Schattenberg Theo de Witte Elly van de Wiel-van Kemenade Harry Dolstra

Minor histocompatibility antigens (mHAgs) constitute the targets of the graft-versus-leukemia response after HLA-identical allogeneic stem cell transplantation. Here, we have used genetic linkage analysis to identify a novel mHAg, designated lymphoid-restricted histocompatibility antigen-1 (LRH-1), which is encoded by the P2X5 gene and elicited an allogeneic CTL response in a patient with chron...

Journal: :Blood 2011
Franck Emmanuel Nicolini Grzegorz W Basak Simona Soverini Giovanni Martinelli Michael J Mauro Martin C Müller Andreas Hochhaus Charles Chuah Inge H Dufva Giovanna Rege-Cambrin Giuseppe Saglio Mauricette Michallet Hélène Labussière Stéphane Morisset Sandrine Hayette Gabriel Etienne Eduardo Olavarria Wei Zhou Senaka Peter Jane F Apperley Jorge Cortes

T315I(+) Philadelphia chromosome-positive leukemias are inherently resistant to all licensed tyrosine kinase inhibitors, and therapeutic options remain limited. We report the outcome of allogeneic stem cell transplantation in 64 patients with documented BCR-ABL(T315I) mutations. Median follow-up was 52 months from mutation detection and 26 months from transplantation. At transplantation, 51.5% ...

Journal: :Blood 2012
Liran I Shlush Noa Chapal-Ilani Rivka Adar Neta Pery Yosef Maruvka Adam Spiro Roni Shouval Jacob M Rowe Maty Tzukerman Dani Bercovich Shai Izraeli Guido Marcucci Clara D Bloomfield Tsila Zuckerman Karl Skorecki Ehud Shapiro

Human cancers display substantial intratumoral genetic heterogeneity, which facilitates tumor survival under changing microenvironmental conditions. Tumor substructure and its effect on disease progression and relapse are incompletely understood. In the present study, a high-throughput method that uses neutral somatic mutations accumulated in individual cells to reconstruct cell lineage trees w...

Journal: :Haematologica 2010
Alois Gratwohl Alvin Schwendener Helen Baldomero Michael Gratwohl Jane Apperley Dietger Niederwieser Karl Frauendorfer

BACKGROUND Innovations in hematology spread rapidly. Factors affecting the speed of introduction, international diffusion, and durability of use of innovations are, however, poorly understood. DESIGN AND METHODS We used data on 251,106 hematopoietic stem cell transplants from 591 teams in 36 European countries to analyze the increase and decrease in such transplants for breast cancer and chro...

Bashir Mirtajani Fatemeh Naeimpour Jafar Aghajani Mahdi Tat, Mohammad Sadegh Hashemzadeh, Mojtaba Sharti Nasim Padasht Omid Lakzaie Azar Ruhollah Dorostkar, Saman Ayoubi

Human T-cell lymphotropic virus type 1 , 2 (HTLV-1, 2) is endemic in Particular Areas of the world in which it is associated with myeloid leukemia.In this study, we described the prevalence of HTLV-1, 2 in myeloid leukemia and Mycobacterium Tuberculosis in Iran. We have worked with tissue and blood samples for 2 years. These were the same samples which were positive for myeloid leukemia, Mycoba...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید